Literature DB >> 29071845

[Review on advantages and evidence of treating and preventing urinary tract infection in traditional Chinese medicine].

Guo-Yong Yu1, Zhe-Jing Tian1, Yue Sun2, Han-Wen Yang1, Shuai-Jie Han1, Run-Pei Miao1, Xin-Wen Fu2, Min Xiong1, Yao-Xian Wang1, Jun-Jian Tian1.   

Abstract

Urinary tract infection (UTI) in traditional Chinese medicine (TCM) belongs to the category of stranguria. This article describes the unsatisfactory situations in clinical practice such as antibiotics abuse, increasing of drug-resistant bacteria, high recurrence rate, etc. According to evidence-based medicine, literatures as evidence are collected for summarizing and analyzing and the result shows the advantages of TCM of relieving symptoms, reducing the dosage of antibiotics, less side effects, lower recurrence rate, etc. In the field of fundamental research, literatures associated with UTI are also summarized and analysed from several perspectives, such as causes, pathogenesis, syndrome differentiation, pharmacological effects of Chinese herbal medicine, working mechanism of non-drug therapy, etc and the result presents that integrated treatment of TCM in UTI has significant advangtages and its own characteristic. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  advantages ; evidence ; stranguria ; traditional Chinese medicine ; urinary tract infection

Mesh:

Substances:

Year:  2017        PMID: 29071845     DOI: 10.19540/j.cnki.cjcmm.2017.0040

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Zishenwan Decreases Kidney Damage in Recurrent Urinary Tract Infection through the Inhibition of Toll-Like Receptor 4 Signal.

Authors:  Guoqiang Liang; Hua Tang; Daolei Ni; Yan Ren; Chenxi Zhang; Wenyi Zheng; Yongliang Song; Xiaofeng Shen; Weimin Jin; Chunbo Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-05       Impact factor: 2.629

2.  Clinical efficacy of Tailin formulation combined with continuous low-dose antimicrobial therapy for recurrent urinary tract infection: study protocol for a multicenter, double-blind, randomized, controlled clinical trial.

Authors:  Tonglu Li; Yingru Xu; Xuezhong Gong
Journal:  Trials       Date:  2021-12-11       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.